Long-term follow-up of patients treated for toxic epidermal necrolysis

Journal of Burn Care and Research

Volumn 27, Issue 1, 2006, Pages 26-33

  Oplatek, Agnes ^a   Brown, Kimberly ^a   Sen, Soman ^a   Halerz, Marcia ^a   Supple, Kathy ^a   Gamelli, Richard L ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; BURN UNIT; CLINICAL ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONFERENCE PAPER; CONTROLLED STUDY; DEPIGMENTATION; DISEASE SEVERITY; EYE DISEASE; FEMALE; FOLLOW UP; HEART FAILURE; HOSPITAL DISCHARGE; HUMAN; KAPLAN MEIER METHOD; KIDNEY DISEASE; KIDNEY FAILURE; LONG TERM CARE; MALE; MORTALITY; MUCOSAL DISEASE; MULTIPLE ORGAN FAILURE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PUNCH BIOPSY; QUESTIONNAIRE; RECURRENT DISEASE; RETROSPECTIVE STUDY; SEPSIS; SURVIVAL RATE; SURVIVAL TIME; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; BURN UNITS; CHICAGO; CICATRIX; COHORT STUDIES; COMORBIDITY; EPIDERMAL NECROLYSIS, TOXIC; EYE DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; MUCOUS MEMBRANE; MULTIVARIATE ANALYSIS; NEVUS; PATIENT ADMISSION; PIGMENTATION DISORDERS; PRURITUS; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 33745664875     PISSN: 1559047X     EISSN: 15590488     Source Type: Journal    
DOI: 10.1097/01.bcr.0000194268.01514.f8     Document Type: Conference Paper

References (26)

1. Riichio A, Tadamichi S, Akihiko S, Hideki N, Hirokazu W, Hiroshi S. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by souluble Fas ligand. Am J Pathol 2003;162:1515-20.
2. Viard I, Wehrli P, Bullani R. Inhibition of toxic epidermal necrolysis by blockade of CD 95 with human intravenous immunoglobulin. Science 1998;282:490-3.
3. Stella M, Cassano P, Bollero D, Clemente A, Giorio G. Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: Our experience. Dermatology 2001;203:45-9.
4. Brown K, Silver G, Halerz M, Walaszek P, Sandroni A, Gamelli R. Toxic epidermal necrolysis: Does immunoglobulin make a difference? J Burn Care Rehabil 2004;25:81-8.
5. Rodger S, Gomez M, Mittman N, Cartotto R. Intravaneous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil 2004;25:246-55.
6. Bachot N, Revuz J, Roujean J. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 2003;139:33-6.
7. Palmieri TL, Greenhalgh DG, Saffle JR, Spence RJA. multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil 2002;23:87-96.
8. Schulz JT, Sheridan RL, Ryan CM, MacKool B, Tompkins G. A 10-year experience with toxic epidermal necrolysis. J Burn Care Rehabil 2000;21:199-204.
9. Ducic I, Shalom A, Rising W, Nagamoto K, Munster A. Outcome of patients with toxic epidermal necrolysis syndrome revisited. Plast Reconstr Surg 2002;110:768-73.
10. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau J, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000;115:149-53.
11. Roujeau JC, Chosidow O, Saiag P, Guillaume JC. Toxic epidermal necrolysis (Lyell syndrome). J Am Acad Dermatol 1990;23:1039-58.
12. Revuz J, Penso D, Roujeau J, et al. Toxic epidermal necrolysis: clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987;123:1160-5.
13. Sheridan RL, Schulz JT, Ryan CM, et al. Long-term consequences of toxic epidermal necrolysis in children. Pediatrics 2002;109:74-8.
14. Magina S, Lisboa C, Leal V, Palmares J, Mesquita-Guimaraes J. Dermatological and ophthalmological sequels in toxic epidermal necrolysis. Dermatology 2003;207:33-6.
15. Haber J, Hopman W, Gomez M, Cartotto R. Late outcomes in adult survivors of toxic epidermal necrolysis after treatment in a burn center. J Burn Care Rehabil 2005;26:33-41.
16. Murphy JT, Purdue GF, Hunt JL. Toxic epidermal necrolysis. J Burn Care Rehabil 1997;18:417.
17. Honari S, Gibran NS, Heimbach DM, Gibbons J, Cain V, Engrav LH. Toxic epidermal necrolysis (TEN) in elderly patients. J Burn Care Rehabil 2001;22:132-5.
18. Engelhardt SL, Schurr MJ, Helgerson RB. Toxic epidermal necrolysis: an analysis of referral patterns and steroid usage. J Burn Care Rehabil 1997;18:520-3.
19. McGee T, Munster A. Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to regional burn center. Plast Reconstr Surg 1998;102:1018-22.
20. Kelemen JJ, Cioffi WG, McManus WF, Mason AD, Pruitt BA. Burn center care for patients with toxic epidermal necrolysis. J Am Coll Surg 1995;180:273-8.
21. Kopf AW, Grupper C, Baer RL, Mitchell JC. Eruptive nevocytic nevi after severe bullous disease. Arch Dermatol 1977;113.
22. Prendiville JS, Herbert AA, Greenwald MJ, Esterly NB. Management of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. J Pediatr 1989;115:881-7.
23. Lehman SS Long term ocular complications of Stevens-Johnson syndrome. Clin Pediatr 1999;38:425-7.
24. Lebargy F, Wolkenstein P, Gisselbrecht M, et al. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med 1997;23:1237-44.
25. McIvor RA, Zaidi J, Peters WJ, Hyland RH. Acute and chronic respiratory complications of toxic epidermal necrolysis. J Burn Care Rehabil 1996;17:237-40.
26. Krumlovsky FA, Del Greco F, Herdson PB. Renal disease associated with toxic epidermal necrolysis (Lyell's disease). Am J Med 1974;57:817-25.